All publications

Export 162 results:
Author Title Type [ Year(Asc)]
2014
Takebe Y., Naito Y., Raghwani J., Fearnhill E, Sano T., Kusagawa S., Mbisa JL, Zhang H, Matano T., Leigh Brown A et al..  2014.  Intercontinental dispersal of HIV-1 subtype B associated with transmission among men who have sex with men in Japan. J Virol. 88:9864-76.
Hue S, Brown A, Ragonnet-Cronin M, Lycett S, Dunn DT, Fearnhill E, Dolling D, Pozniak A, Pillay D, Delpech V et al..  2014.  Phylogenetic analyses reveal HIV-1 infections between men misclassified as heterosexual transmissions. AIDS. 28:1967-75.
Hodcroft E, Hadfield J, Fearnhill E, Phillips AN, Dunn DT, O’Shea S, Pillay D, Leigh Brown A.  2014.  The contribution of viral genotype to plasma viral set-point in HIV infection. PLoS Pathog. 10:e1004112.
UK HIV Drug Resistance Database.  2014.  The increasing genetic diversity of HIV-1 in the UK, 2002-2010. AIDS. 28:773-80.
Bulteel N, Bansi-Matharu L., Churchill D, Dunn DT, Bibby D., Hill T, Sabin CA, Nelson M.  2014.  The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort. J Infect. 68:77-84.
Foster GM, Ambrose JC, Hue S, Delpech V, Fearnhill E, Abecasis AB, Leigh Brown A, Geretti AM.  2014.  Novel HIV-1 recombinants spreading across multiple risk groups in the United Kingdom: the identification and phylogeography of Circulating Recombinant Form (CRF) 50_A1D. PLoS One. 9:e83337.
K Bouzidi E, White E, Mbisa JL, Phillips AN, Mackie N, Pozniak A, Dunn DT.  2014.  Protease mutations emergining on darunavir in protease inhibitor-naive and experienced patients in the UK. International Congress of Drug Therapy in HIV Infection, November 2014.
Hodcroft E, Hadfield J, Fearnhill E, Phillips AN, Dunn DT, Pillay D, Leigh Brown A, UK HIV Drug Resistance Database.  2014.  HIV Virulence has not increased in the UK subtype B epidemic. Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014.
Mbisa JL, Fearnhill E, Dunn DT, Pillay D, Cane P A, UK HIV Drug Resistance Database.  2014.  Sustained Spread of HIV-1 Drug Resistance in Treatment-Naïve Patients in the United Kingdom. Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014.
Mourad R, Chevennet F, Dunn DT, Fearnhill E, Asboe D, Gascuel O, Hue S.  2014.  Transmission and persistence of antiretroviral resistance amongst drug naïve HIV positive individuals in the United Kingdom. International Workshop on Antiviral Drug Resistance, June 2014.
Croxford S, Chau C, Skingsley A, Tostevin A, Dolling D, Delpech V, UK HIV Drug Resistance Database.  2014.  National audit of baseline HIV resistance testing among newly-diagnosed adults. Third Joint Conference of BHIVA and BASHH, 1-14 April 2014.
Cambiano V, Castro H, Chadwick D, Smit E, Geretti AM, Dunn DT, Phillips AN, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2014.  Detection of NNRTI resistance mutations after interrupting NNRTI-based regimens. Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014.
2013
Castro H, Pillay D, Cane P A, Asboe D, Cambiano V, Phillips AN, Dunn DT.  2013.  Persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis. 208:1459-63.
Ragonnet-Cronin M, Hodcroft E, Hue S, Fearnhill E, Delpech V, Leigh Brown A, Lycett S.  2013.  Automated analysis of phylogenetic clusters. BMC Bioinformatics. 14:317.
Dolling D, Dunn DT, Sutherland K.A, Pillay D, Mbisa JL, Parry C.M, Post FA, Sabin CA, Cane P A.  2013.  Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study. J Antimicrob Chemother. 68:2339-43.
Santoro MM, Sabin CA, Forbici F., Bansi L, Dunn DT, Fearnhill E, Boumis E, Nicastri E., Antinori AM, Palamara G et al..  2013.  Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. HIV Med. 14:571-7.
Mackie N, Dunn DT, Dolling D, Garvey L, Harrison LJ, Fearnhill E, Tilston P, Sabin CA, Geretti AM.  2013.  The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults. AIDS. 27:2245-53.
Koning FA, Castro H, Dunn DT, Tilston P, Cane P A, Mbisa JL.  2013.  Subtype-specific differences in the development of accessory mutations associated with high-level resistance to HIV-1 nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother. 68:1220-36.
De Luca A., Dunn DT, Zazzi M, Camacho R., Torti C., Fanti I., Kaiser R., Sonnerborg A., Codoner F.M, Van Laethem K. et al..  2013.  Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis. 207:1216-20.
Dolling D, Dunn DT, Geretti AM, Sabin CA.  2013.  HIV-1 subtype and virological response to antiretroviral therapy: a confirmatory analysis. Clin Infect Dis. 56:162-3.